|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM347547168 |
003 |
DE-627 |
005 |
20231226034101.0 |
007 |
cr uuu---uuuuu |
008 |
231226s2022 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.3928/23258160-20220914-01
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1158.xml
|
035 |
|
|
|a (DE-627)NLM347547168
|
035 |
|
|
|a (NLM)36239676
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Richardson, Quintin R
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 18.10.2022
|
500 |
|
|
|a Date Revised 22.12.2022
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a BACKGROUND AND OBJECTIVE: Macular atrophy (MA) contributes to declining vision during prolonged anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) so greater understanding of its incidence, evolution, and impact on visual acuity is merited
|
520 |
|
|
|a MATERIALS AND METHODS: This is a retrospective review of nAMD patients receiving anti-VEGF therapy for ≥ 5 years. Near-infrared reflectance images and vision data were extracted every 6 months. MA lesion areas were measured using ImageJ
|
520 |
|
|
|a RESULTS: Vision showed a mean decline of -1.2 letters/year. Eyes with MA showed a greater decrease of -1.6 letters/year compared to eyes without MA (-0.7 letters/year). Cumulative incidence of MA was 38% at 5 years. MA was significantly associated with declining vision, showing a -0.7 letter decrease for every 1 mm2 increase in lesion size
|
520 |
|
|
|a CONCLUSION: Over a 5-year course of nAMD treatment, MA affected most eyes, and MA progression was significantly associated with vision decline. [Ophthalmic Surg Lasers Imaging Retina 2022;53:546-552.]
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
650 |
|
7 |
|a Endothelial Growth Factors
|2 NLM
|
650 |
|
7 |
|a Vascular Endothelial Growth Factor A
|2 NLM
|
650 |
|
7 |
|a Ranibizumab
|2 NLM
|
650 |
|
7 |
|a ZL1R02VT79
|2 NLM
|
700 |
1 |
|
|a Zhang, Youning
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Deiner, Michael S
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Wang, Suling T
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Bhisitkul, Jonah M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Arnold, Benjamin F
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Bhisitkul, Robert B
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 53(2022), 10 vom: 17. Okt., Seite 546-552
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnns
|
773 |
1 |
8 |
|g volume:53
|g year:2022
|g number:10
|g day:17
|g month:10
|g pages:546-552
|
856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20220914-01
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_31
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_63
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_69
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_90
|
912 |
|
|
|a GBV_ILN_91
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_135
|
912 |
|
|
|a GBV_ILN_136
|
912 |
|
|
|a GBV_ILN_151
|
912 |
|
|
|a GBV_ILN_181
|
912 |
|
|
|a GBV_ILN_203
|
912 |
|
|
|a GBV_ILN_217
|
912 |
|
|
|a GBV_ILN_235
|
912 |
|
|
|a GBV_ILN_289
|
912 |
|
|
|a GBV_ILN_294
|
912 |
|
|
|a GBV_ILN_297
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_352
|
912 |
|
|
|a GBV_ILN_674
|
912 |
|
|
|a GBV_ILN_676
|
912 |
|
|
|a GBV_ILN_688
|
912 |
|
|
|a GBV_ILN_698
|
912 |
|
|
|a GBV_ILN_721
|
912 |
|
|
|a GBV_ILN_737
|
912 |
|
|
|a GBV_ILN_791
|
912 |
|
|
|a GBV_ILN_812
|
951 |
|
|
|a AR
|
952 |
|
|
|d 53
|j 2022
|e 10
|b 17
|c 10
|h 546-552
|